

SEP 15 2006

Serial No. 10/628,933
Attorney Docket No. IN01481KC

optionally substituted with 1-4 substituents which can be the same or different and are independently selected from the group consisting of R^{11} , R^{12} , R^{13} , R^{14} and R^{15} ;

R^4 is 1-3 ~~substituents selected from the group consisting of cycloheteroalkyl, $C(O)C_3-C_8$ cycloalkyl, $C(O)C_3-C_8$ cycloheteroalkyl, $-(C_1-C_6)$ alkyl- $N(R^{21})SO_2R^{22}$, $-(C_4-C_6)$ alkyl- $C(O)NR^{20}R^{24}$, $C(O)-(C_4-C_6)$ alkyl, R^8 -aryl- $C(O)$, $C(O)N(H)OH$, (C_4-C_6) alkyl- $N(R^{24})C(O)R^{22}$, (C_4-C_6) alkyl- $N(R^{24})CO_2R^{22}$, (C_4-C_6) alkyl- $N(R^{24})C(O)NR^{21}R^{22}$, (C_4-C_6) alkyl- $NR^{24}R^{22}$, (C_4-C_6) alkyl- NH_2 , (C_4-C_6) alkyl- $SO_2NR^{24}R^{22}$ and $SO_2NR^{24}R^{22}$, wherein R^4 can be the same or different and is independently selected when there is more than one R^4 present;~~

R^5 ~~is selected from the group consisting of H, arylalkyl, (C_4-C_6) alkyl, R^8 -aryl- (C_4-C_6) alkyl, R^8 -heteroaryl- (C_4-C_6) alkyl, $SO_2-(C_1-C_6)$ alkyl, $SO_2-(C_3-C_6)$ cycloalkyl, SO_2 -aryl, R^8 -aryl- SO_2 , $C(O)-(C_4-C_6)$ alkyl, $C(O)-(C_4-C_6)$ cycloalkyl, R^8 -aryl- $C(O)$, $C(O)NR^{24}R^{22}$, and $SO_2NR^{24}R^{22}$;~~

R^6 is H, (C_4-C_6) alkyl, or (C_4-C_6) haloalkyl;

R^7 is selected from the group consisting of aryl, substituted aryl, heteroaryl, alkyl, haloalkyl and cycloalkyl;

R^8 is 1, 2 or 3 ~~substituents selected from the group consisting of H, halo, (C_4-C_6) alkyl, (C_4-C_6) alkoxy, CF_3 , OCF_3 , $CH_3C(O)$, CN , CH_3SO_2 , CF_3SO_2 and NH_2 , wherein R^8 can be the same or different and is independently selected when there are more than one R^8 present;~~

R^9 , R^{10} and B can be the same or different and are each independently selected from the group consisting of hydrogen, (C_1-C_6) alkyl, and $-(C_1-C_6)$ haloalkyl;

R^{11} and R^{12} can be the same or different and are each independently selected from the group consisting of (C_1-C_6) alkyl, $-(C_1-C_6)$ haloalkyl, halogen, $-NR^{19}R^{20}$, $-OH$, CF_3 , $-OCH_3$, $-O$ -acyl, and $-OCF_3$;

R^{13} is selected from the group consisting of hydrogen, R^{11} , H, phenyl, $-NO_2$, $-CN$, $-CH_2F$, $-CHF_2$, $-CHO$, ~~$-CH=NOR_{487}$, $-CH=NOR^{19}$~~ , pyridyl-N-oxide, pyrimidinyl, pyrazinyl, ~~$N(R^{20})CONR^{20}R^{24}$, $N(R^{20})CONR^{20}R^{21}$~~ , $-NHCONH$ (chloro- (C_1-C_6) alkyl), $-NHCONH$ ((C_3-C_{10})-cycloalkyl(C_1-C_6 alkyl), $-NHCO$ (C_1-C_6 alkyl), $-NHCOCF_3$, $-NHCOCF_3$, $-NHCO_2N$ ((C_1-C_6 alkyl) $_2$, $-NHCO_2$ (C_1-C_6 alkyl), $-N(SO_2CF_3)_2$, $-NHCO_2$ (C_1-C_6 alkyl), (C_3-C_{10}) cycloalkyl, -

Serial No. 10/628,933
Attorney Docket No. IN01481KC

SR²², -SOR²², -SO₂R²², -SO₂NH(C₁-C₆ alkyl), -OSO₂(C₁-C₆)alkyl, -OSO₂CF₃, hydroxy(C₁-C₆)alkyl, -CONR¹⁹R²⁰, -CON(CH₂CH₂-O-CH₃)₂, -OCONH(C₁-C₆)alkyl, -CO₂R¹⁹, -Si(CH₃)₃ and -B(OC(CH₃)₂)₂;

R¹⁴ is selected from the group consisting of (C₁-C₆)alkyl, -(C₁-C₆)haloalkyl -NH₂ and R¹⁵-phenyl;

R¹⁵ is 1-3 substituents selected from the group consisting of hydrogen, (C₁-C₆)alkyl, -(C₁-C₆)haloalkyl, -CF₃, -CO₂R²⁰, -CN, (C₁-C₆)alkoxy and halogen; wherein R¹⁵ can be the same or different and is independently selected when there are more than one R¹⁵ present;

~~R¹⁶ and R¹⁷ can each be the same or different and are each independently selected from the group consisting of hydrogen and (C₁-C₆)alkyl, or~~

~~R¹⁶ and R¹⁷ together are a C₂-C₆ alkylene group and with the carbon to which they are attached from a spiro ring of 3 to 6 carbon atoms;~~

R¹⁹, R²⁰ and R²¹ can each be the same or different and are each independently selected from the group consisting of H, (C₁-C₆)alkyl and (C₃-C₆)cycloalkyl;

R²² is selected from the group consisting of (C₁-C₆)alkyl, -(C₁-C₆)haloalkyl, (C₂-C₆)hydroxyalkyl, (C₂-C₆)alkylene, (C₃-C₆)cycloalkyl, aryl and aryl(C₁-C₆)alkyl-;

A is selected from the group consisting of H, (C₁-C₆)alkyl, and (C₂-C₆) alkenyl.































M is aryl ~~or heteroaryl~~ optionally substituted with R⁴, wherein said aryl is phenyl; and

Q is CH or N, with the following proviso:

























when R¹ is phenyl, ~~pyridyl, thiophenyl or naphthyl~~, R² cannot be H, -(C₁-C₆)alkyl or -C(O)-(C₁-C₆)alkyl.

22. (Amended) A compound having the structural formula I according to claim 21 wherein R⁹, R¹⁰ and B are H, A is -CH₃, and R¹, R² and R³ are as defined in the following table:

Serial No. 10/628,933
Attorney Docket No. IN01481KC

| # | R ¹ | R ² | R ³ |
|----|---|---|---|
| 1 |  |  |  |
| 2 |  |  |  |
| 3 |  |  |  |
| 4 |  |  |  |
| 5 |  |  |  |
| 6 |  |  |  |
| 7 |  |  |  |
| 45 |  |  |  |
| 47 |  |  |  |
| 48 |  |  |  |

Serial No. 10/628,933
Attorney Docket No. IN01481KC


| | | | |
|-----|---|---|---|
| 49 |  |  |  |
| 54 |  |  |  |
| 55 |  |  |  |
| 56 |  |  |  |
| 57 |  |  |  |
| 64 |  |  |  |
| 412 |  |  |  |
| 443 |  |  |  |

23. (Amended) A compound according to claim 22 wherein R¹, R² and R³ each represent:




Serial No. 10/628,933
Attorney Docket No. IN01481KC

| # | R ¹ | R ² | R ³ |
|----|----------------|----------------|----------------|
| 4 | | | |
| 2 | | | |
| 6 | | | |
| 47 | | | |
| 49 | | | |
| 56 | | | |
| 57 | | | |

24. (Amended) A compound according to claim 23 represented by the structural formulae:



Serial No. 10/628,933
Attorney Docket No. IN01481KC



25. (Previously presented) A pharmaceutical composition comprising one or more compounds of claim 21.
26. (Previously presented) A pharmaceutical composition comprising one or more compounds of claim 24.
27. (Previously presented) The pharmaceutical composition according to claim 25 further comprising one or more pharmaceutically acceptable carriers.
28. (Previously presented) The pharmaceutical composition according to claim 26 further comprising one or more pharmaceutically acceptable carriers.
29. (Previously presented) The pharmaceutical composition according to claim 25, wherein said pharmaceutical composition contains a therapeutically effective amount of said one or more compounds.

Serial No. 10/628,933
Attorney Docket No. IN01481KC

30. (Previously presented) The pharmaceutical composition according to claim 26, wherein said pharmaceutical composition contains a therapeutically effective amount of said one or more compounds.

31-40. (Previously canceled)